30 November 2020 - Karolinska Development announces today that the U.S. FDA has granted fast track designation for eprenetapopt in the treatment of patients with TP53 mutant acute myeloid leukaemia.
The company previously received breakthrough therapy, orphan drug and fast track designations for eprenetapopt in the treatment of patients with TP53 mutant myelodysplastic syndromes.